Cascade Financial Partners LLC Decreases Stock Holdings in FibroBiologics, Inc. (NASDAQ:FBLG)

Cascade Financial Partners LLC lowered its stake in shares of FibroBiologics, Inc. (NASDAQ:FBLG) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 282,601 shares of the company’s stock after selling 20,000 shares during the period. Cascade Financial Partners LLC’s holdings in FibroBiologics were worth $565,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of FibroBiologics by 90.0% in the third quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock valued at $1,854,000 after purchasing an additional 284,047 shares in the last quarter. Barclays PLC lifted its holdings in shares of FibroBiologics by 363.2% in the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after purchasing an additional 31,331 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of FibroBiologics in the third quarter valued at about $37,000. State Street Corp lifted its holdings in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after purchasing an additional 99,789 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of FibroBiologics in the third quarter valued at about $32,000.

FibroBiologics Price Performance

Shares of FBLG opened at $1.10 on Wednesday. FibroBiologics, Inc. has a 1 year low of $0.98 and a 1 year high of $13.59. The company’s 50 day simple moving average is $1.57 and its 200 day simple moving average is $2.27.

Wall Street Analysts Forecast Growth

FBLG has been the topic of several recent research reports. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price target on the stock. D. Boral Capital reissued a “buy” rating and set a $16.00 price objective on shares of FibroBiologics in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of FibroBiologics in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.